BR112012011518B8 - Compostos, composição farmacêutica, kit e usos de um composto - Google Patents

Compostos, composição farmacêutica, kit e usos de um composto

Info

Publication number
BR112012011518B8
BR112012011518B8 BR112012011518A BR112012011518A BR112012011518B8 BR 112012011518 B8 BR112012011518 B8 BR 112012011518B8 BR 112012011518 A BR112012011518 A BR 112012011518A BR 112012011518 A BR112012011518 A BR 112012011518A BR 112012011518 B8 BR112012011518 B8 BR 112012011518B8
Authority
BR
Brazil
Prior art keywords
compound
kit
pharmaceutical composition
methyl
compounds
Prior art date
Application number
BR112012011518A
Other languages
English (en)
Other versions
BR112012011518B1 (pt
BR112012011518A2 (pt
Inventor
Cantin Louis-David
Luo Xuehong
Jerzy Tomaszewski Miroslaw
Original Assignee
Astrazeneca Ab
Neomed Inst
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Neomed Inst, Bellus Health Cough Inc filed Critical Astrazeneca Ab
Publication of BR112012011518A2 publication Critical patent/BR112012011518A2/pt
Publication of BR112012011518B1 publication Critical patent/BR112012011518B1/pt
Publication of BR112012011518B8 publication Critical patent/BR112012011518B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, KIT, USO DE UM COMPOSTO, E, MÉTODOS PARA TRATAR UM DISTÚRBIO E PARA TRATAR A DOR Esta invenção geralmente se refere a compostos de benzoimidazol substituídos, particularmente 2-((2-(2,6-difluoro-4-(metil-carbamoil)fenil)-5-metil-1H-benzol[d]imidazol-1-il)morfolino-4-carboxilato de metila e sais dos mesmos. Esta invenção também se refere às composições farmacêuticas e kits que compreendem um tal composto, usos de um tal composto (incluindo, por exemplo, métodos de tratamento e preparações de medicamento), processos para fabricar um tal composto, e intermediários usados em tais processos.
BR112012011518A 2009-11-18 2010-11-17 Compostos, composição farmacêutica, kit e usos de um composto BR112012011518B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18
US61/262263 2009-11-18
PCT/SE2010/051269 WO2011062550A1 (en) 2009-11-18 2010-11-17 Benzoimidazole compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR112012011518A2 BR112012011518A2 (pt) 2016-06-28
BR112012011518B1 BR112012011518B1 (pt) 2020-03-10
BR112012011518B8 true BR112012011518B8 (pt) 2023-01-10

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011518A BR112012011518B8 (pt) 2009-11-18 2010-11-17 Compostos, composição farmacêutica, kit e usos de um composto

Country Status (16)

Country Link
US (1) US8530467B2 (pt)
EP (1) EP2501697B1 (pt)
JP (1) JP5657018B2 (pt)
KR (1) KR20120113709A (pt)
CN (1) CN102741245B (pt)
AR (1) AR079050A1 (pt)
AU (1) AU2010322478B2 (pt)
BR (1) BR112012011518B8 (pt)
CA (1) CA2777746C (pt)
ES (1) ES2442797T3 (pt)
IN (1) IN2012DN03391A (pt)
MX (1) MX2012005329A (pt)
RU (1) RU2542582C2 (pt)
TW (1) TW201121957A (pt)
UY (1) UY33037A (pt)
WO (1) WO2011062550A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
PL3381917T3 (pl) * 2013-01-31 2021-12-27 Bellus Health Cough Inc. Związki imidazopirydynowe i i ch zastosowania
JP6632127B2 (ja) * 2013-12-20 2020-01-15 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
EP3164132A4 (en) * 2014-07-03 2018-02-21 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
WO2020135771A1 (zh) * 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
BR112023001924A2 (pt) * 2020-08-13 2023-03-07 Tuojie Biotech Shanghai Co Ltd Derivados de benzimidazol, método de preparo para os mesmos e uso médico dos mesmos
WO2022117062A1 (zh) * 2020-12-04 2022-06-09 上海拓界生物医药科技有限公司 含有稠合三环的化合物及其医药用途
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
WO2023151658A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的可药用盐及其制备方法
TW202342468A (zh) * 2022-02-11 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的晶型及其製備方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DK1154774T3 (da) 1999-02-10 2005-09-26 Astrazeneca Ab Quinazolinderivater som angiogenesisinhibitorer
PT1249450E (pt) * 2000-01-17 2008-01-02 Teijin Pharma Ltd Derivados de benzimidazole como inibidores de quimase humana
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CZ200331A3 (cs) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
KR20090127902A (ko) * 2007-03-02 2009-12-14 쉐링 코포레이션 벤즈이미다졸 유도체 및 이의 사용방법
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
AU2008319308B2 (en) * 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
AU2010322478A1 (en) 2012-05-31
BR112012011518B1 (pt) 2020-03-10
EP2501697A4 (en) 2013-04-24
CN102741245A (zh) 2012-10-17
MX2012005329A (es) 2012-05-29
AR079050A1 (es) 2011-12-21
TW201121957A (en) 2011-07-01
RU2542582C2 (ru) 2015-02-20
CN102741245B (zh) 2014-11-05
EP2501697A1 (en) 2012-09-26
RU2012124268A (ru) 2013-12-27
US20120289504A1 (en) 2012-11-15
WO2011062550A1 (en) 2011-05-26
CA2777746A1 (en) 2011-05-26
US8530467B2 (en) 2013-09-10
JP2013511517A (ja) 2013-04-04
JP5657018B2 (ja) 2015-01-21
BR112012011518A2 (pt) 2016-06-28
IN2012DN03391A (pt) 2015-10-23
UY33037A (es) 2011-06-30
ES2442797T3 (es) 2014-02-13
AU2010322478B2 (en) 2013-11-14
CA2777746C (en) 2019-05-14
EP2501697B1 (en) 2013-10-23
KR20120113709A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
BR112012011518B8 (pt) Compostos, composição farmacêutica, kit e usos de um composto
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BRPI0821994B8 (pt) composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
CL2007003870A1 (es) Uso de compuestos derivados de acido 1-(3-piridinil)pirazol-4-il-aceticos; dichos compuestos derivados o una de sus sales; procedimiento de preparacion de dichos compuestos; agente herbicida o regulador del crecimiento de las plantas; y procedimiento
BRPI0806365B8 (pt) composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
CL2007001941A1 (es) Compuestos derivados de 1-aril-5-alquilo pirazol; composicion para tratar animales contra ectoparasitos; uso de dicha composicion; composicion insecticida; uso de dichos compuestos derivados; metodo para preparar composiciones pesticidas; metodo para
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
BR112015018317A2 (pt) composto de fórmula i ou um sal do mesmo, composição farmacêutica, kit, uso de um composto ou sal, método para tratar um distúrbio, método para tratar dor em um animal
BRPI0507198A (pt) derivados de bisariluréia
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
BR112012021659A2 (pt) composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças.
BR112013006030A2 (pt) composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica
BR112012022064A2 (pt) tratamento de artrite lúpica usando laquinimod
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BR112012021656A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BR112012009496A2 (pt) composição farmacêutica, e, método para tratar diabetes tipo 2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: NEOMED INSTITUTE (CA)

B25A Requested transfer of rights approved

Owner name: BELLUS HEALTH COUGH INC. (CA)